Press Release – New York, NY – July 16, 2020 – Sichenzia Ross Ference LLP announced that it represented Equillium, Inc. (NASDAQ: “EQ”), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, in an At-The-Market Offering (“ATM”), whereby Equillium may sell up to $150 million of common stock from time-to-time. Jefferies LLC is acting as the sales agent in connection with the ATM.
The shares were registered on Equillium’s Registration Statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on November 25, 2019 (File No. 333-234683) and the prospectus supplement relating to the ATM dated July 14, 2020.
The Sichenzia Ross Ference LLP team was led by partners Marc J. Ross and James M. Turner.
[starbox id=1]
